Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCheckit Regulatory News (CKT)

Share Price Information for Checkit (CKT)

Share Price is delayed by 15 minutes
Get Live Data
24.00    -1.00 (-4.00%)
Bid:
23.00
Ask:
25.00
Spread: 2.00 (8.696%)
Market Cap: £25.92m
CKT Live PriceLast checked at - London Stock Exchange

Intraday Checkit Share Chart

Form 8 (OPD) - Checkit plc

12 Jun 2024 15:22

RNS Number : 1970S
Checkit PLC
12 June 2024
Β 

FORM 8 (OPD)

Β 

PUBLIC OPENING POSITION DISCLOSURE BY A PARTY TO AN OFFER

Rules 8.1 and 8.2 of the Takeover Code (the "Code")

Β 

1. KEY INFORMATION

Β 

(a) Full name of discloser:

Checkit plc

(b) Owner or controller of interests and short positions disclosed, if different from 1(a):

The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.

N/A

(c) Name of offeror/offeree in relation to whose relevant securities this form relates:

Use a separate form for each offeror/offeree

Checkit plc

(d) Is the discloser the offeror or the offeree?

Offeror

(e) Date position held:

The latest practicable date prior to the disclosure

11th June 2024

(f) In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer?

If it is a cash offer or possible cash offer, state "N/A"

No

Β 

2. POSITIONS OF THE PARTY TO THE OFFER MAKING THE DISCLOSURE

Β 

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

Β 

(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates

Β 

Class of relevant security:

Β 

Β 

Β 

Β 

Interests

Short positions

Number

%

Number

%

(1) Relevant securities owned and/or controlled:

Nil

Nil

Nil

Nil

(2) Cash-settled derivatives:

Β 

Nil

Nil

Nil

Nil

(3) Stock-settled derivatives (including options) and agreements to purchase/sell:

Nil

Nil

Nil

Nil

Β 

TOTAL:

Nil

Nil

Nil

Nil

Β 

All interests and all short positions should be disclosed.

Β 

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental FormΒ 8 (Open Positions).

Β 

Details of any securities borrowing and lending positions or financial collateral arrangements should be disclosed on a Supplemental Form 8 (SBL).

Β 

(b) Rights to subscribe for new securities

Β 

Class of relevant security in relation to which subscription right exists:

None

Details, including nature of the rights concerned and relevant percentages:

None

Β 

Β 

3. POSITIONS OF PERSONS ACTING IN CONCERT WITH THE PARTY TO THE OFFER MAKING THE DISCLOSURE

Β 

Details of any interests, short positions and rights to subscribe (including directors' and other employee options) of any person acting in concert with the party to the offer making the disclosure:

Β 

(A) Interests held by directors of Checkit plc and their close relatives and related trusts

Β 

Β 

Β 

Name

Β 

Number of shares

Percentage of total issued share capital of Checkit plc

Keith Daley

Β 

21,525,366

19.93%

Christopher Kyte

Β 

167,872

0.16%

Gregory Price

Β 

54,350

0.05%

Simon Greenman

Β 

56,347

0.05%

Alexandra Curran

Β 

1,600

0.01%

Β 

(B) Interests held by directors of Checkit plc under its Enterprise Management Incentive Plan approved in May 2020 and its Company Share Option Plan adopted in March 2022

Β 

Β 

Name

Number of shares (under option)

Date of grant

Vesting date

Expiry date

Exercise price (per share)

Gregory Price

Β 

100,000

17 February 2021

17 February 2024

17 February 2031

55.5p

Gregory Price

845,653

9 January 2023

9 July 2025

9 January 2033

23p

Christopher Kyte

1,500,000*

25 March 2022

from 25 March 2025

From 25 March 2025

0.05p

Christopher Kyte

500,000

9 January 2023

9 January 2026

9 January 2033

23p

Β 

\* The options shall vest in three tranches of 500,000, with the first tranche vesting (subject to the satisfaction of certain conditions being met) 10 business days after the publication of the audited consolidated accounts of the group for the financial years ended 31 January 2025, 31 January 2026 and 31 January 2027. Accordingly, the 500k options tranches will expire in or around March 2025, March 2026 and March 2027 if exercise conditions are not met.

Β 

Β 

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

Β 

Details of any securities borrowing and lending positions or financial collateral arrangements should be disclosed on a Supplemental Form 8 (SBL).

Β 

4. OTHER INFORMATION

Β 

(a) Indemnity and other dealing arrangements

Β 

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the party to the offer making the disclosure or any person acting in concert with it:

Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state "none"

None

Β 

Β 

Β 

(b) Agreements, arrangements or understandings relating to options or derivatives

Β 

Details of any agreement, arrangement or understanding, formal or informal, between the party to the offer making the disclosure, or any person acting in concert with it, and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state "none"

None

Β 

Β 

Β 

(c) Attachments

Β 

Are any Supplemental Forms attached?

Β 

Supplemental Form 8 (Open Positions)

NO

Supplemental Form 8 (SBL)

NO

Β 

Β 

Date of disclosure:

12th June 2024

Contact name:

Hugh Wooster

Telephone number:

0755354180

Β 

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

Β 

The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.

Β 

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.

Β 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Β 
END
Β 
Β 
FEEGPUUPQUPCGCP
Date   Source Headline
22nd Feb 20167:00 amRNSTrading Update
26th Jan 20167:00 amRNSDirectorate Change
20th Jan 20163:22 pmRNSHolding(s) in Company
25th Nov 20157:00 amRNSProduct Launch
24th Nov 20153:21 pmRNSHolding(s) in Company
10th Nov 20157:00 amRNSTrading Update
19th Oct 20153:41 pmRNSDerivative Claim - Update
5th Oct 20157:00 amRNSProduct Launch
28th Sep 20157:00 amRNSDirector's Dealing
14th Sep 20154:12 pmRNSDirector's dealing
10th Sep 20157:00 amRNSDirectorate Changes
10th Sep 20157:00 amRNSHalf Yearly Report
30th Jul 20154:45 pmRNSResult of AGM
23rd Jul 20159:00 amRNSTrading Update
22nd Jul 20157:00 amRNSDerivative claim - update
16th Jul 20154:09 pmRNSDerivative Claim - Update
8th Jul 20153:16 pmRNSLapse of Options
6th Jul 20153:49 pmRNSNotice of AGM
26th Jun 20154:00 pmRNSHolding(s) in Company
18th Jun 20158:50 amRNSDerivative Claim - Update
12th Jun 20154:42 pmRNSAnnual Report and Financial Statements
30th Apr 20157:00 amRNSFinal Results
27th Apr 20155:35 pmRNSHolding(s) in Company
7th Apr 20151:41 pmRNSHolding(s) in Company
12th Feb 20157:00 amRNSYear end trading update
28th Jan 201512:45 pmRNSDerivative Claim - Further Update
24th Nov 20147:00 amRNSTrading update
2nd Oct 20147:00 amRNSDerivative Claim - Update
31st Jul 20146:06 pmRNSResult of AGM
31st Jul 20147:00 amRNSAGM Statement
25th Jul 201411:15 amRNSDirector/PDMR Shareholding
17th Jul 201412:15 pmRNSResult of Open Offer
9th Jul 20148:00 amRNSNotice of AGM
25th Jun 20145:42 pmRNSHolding(s) in Company
23rd Jun 20147:00 amRNSPlacing and Proposed Open Offer
23rd Jun 20147:00 amRNSUnaudited full year results
20th Jun 20147:00 amRNSConclusion of Strategic Alternatives Process
17th Jun 20147:00 amRNSStatement regarding Elektron Technology plc
2nd Jun 20145:33 pmRNSForm 8 (OPD) Microgen plc
2nd Jun 201412:35 pmRNSForm 8.3 - [Microgen Plc]
27th May 20142:10 pmRNSStatement re Elektron Technology Plc
21st May 20149:00 amRNSResponse to Microgen
20th May 201412:39 pmRNSFurther Statement Re Elektron Technology Plc
20th May 201410:20 amRNSStatement re Elektron Technology
13th May 20143:20 pmRNSStrategic Alternatives Process Update
29th Apr 201410:09 amRNSHolding(s) in Company - Replacement
25th Apr 20142:03 pmRNSForm 8.3 - Elektron Technology Plc
25th Apr 20141:45 pmRNSForm 8 (DD) - [Elektron Technology PLC]
23rd Apr 20145:32 pmRNSForm 8.3 - [Elektron Technology Plc]
23rd Apr 20143:22 pmRNSForm 8.3 - [Elektron Technology]

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.